Chemours Co
For the period ended Mar 31, 2024. Filed Apr 30, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed Apr 30, 2024
CC$13.48+1.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Interim Consolidated Statements of Operations (Unaudited)
| Three Months Ended March 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Net sales | $1,350 | $1,536 |
| Cost of goods sold | 1,064 | 1,168 |
| Gross profit | 286 | 368 |
| Selling, general, and administrative expense | 142 | 124 |
| Research and development expense | 28 | 26 |
| Restructuring, asset-related, and other charges | 4 | 16 |
| Total other operating expenses | 174 | 166 |
| Equity in earnings of affiliates | 13 | 12 |
| Interest expense, net | (63) | (42) |
| Other income, net | 5 | 1 |
| Income before income taxes | 67 | 173 |
| Provision for income taxes | 15 | 28 |
| Net income | 52 | 145 |
| Net income attributable to Chemours | $52 | $145 |
| Per share data | ||
| Basic earnings per share of common stock | $0.35 | $0.97 |
| Diluted earnings per share of common stock | 0.34 | 0.96 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.